1. Generics Bulletin
  3. >>Biosimilars

What’s Next? Five Things To Look Out For In June

Formycon Awaits FDA Aflibercept Date; Chinese Patent For Roxadustat Reaches End

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for June 2024.

What's Next Image

Formycon will find out in June whether its FYB203 proposed biosimilar to Eylea (aflibercept) will receive US Food and Drug Administration approval, in the wake of the agency approving last month the first biosimilars to the world’s leading anti-VEGF brand to treat wet age-related macular degeneration.

The German-based developer and its license partner Klinge Biopharma revealed last August that they had obtained a June target action...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

Medicines UK’s Samuels: Off-Patent Drugs Are Finally Gov’s Priority But The Picture Still ‘Nuanced’

 
• By Urtė Fultinavičiūtė

The importance of generic and biosimilar medicines is being recognized by the UK government for the first time. But, as Medicines UK’s CEO Mark Samuels tells Generics Bulletin, companies are still facing multiple hurdles in the market.

BC Partners Bids For Biogaran Buyout – But Will It Face French Pushback?

 
• By Dave Wallace

Private equity firm BC Partners has revealed that it is in exclusive negotiations to acquire Servier’s French generics and biosimilars business Biogaran. But with France’s government having expressed opposition to the sale, could there be strings attached?

Roche Braces For Late 2026 Biosimilar Wave

 
• By Dean Rudge

Roche expects biosimilars to Perjeta and Xolair by the end of 2026, marking a key inflection point for two of its major franchises. Shanghai Henlius Biotech leads development for pertuzumab, while Celltrion is positioned as the frontrunner for omalizumab.

Sandoz Strikes $300m Deal With Just-Evotec For French Biosimilars Site

 
• By Dave Wallace

Sandoz has made yet another major move to further bolster its booming biosimilars business, striking a $300m deal to acquire outright a French development and manufacturing facility from existing biosimilars partner Just-Evotec Biologics.

More from Products